1. Home
  2. SPRY vs NVAX Comparison

SPRY vs NVAX Comparison

Compare SPRY & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRY
  • NVAX
  • Stock Information
  • Founded
  • SPRY 2015
  • NVAX 1987
  • Country
  • SPRY United States
  • NVAX United States
  • Employees
  • SPRY N/A
  • NVAX N/A
  • Industry
  • SPRY Biotechnology: Pharmaceutical Preparations
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SPRY Health Care
  • NVAX Health Care
  • Exchange
  • SPRY Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • SPRY 1.1B
  • NVAX 1.3B
  • IPO Year
  • SPRY N/A
  • NVAX 1995
  • Fundamental
  • Price
  • SPRY $11.24
  • NVAX $7.99
  • Analyst Decision
  • SPRY Strong Buy
  • NVAX Buy
  • Analyst Count
  • SPRY 4
  • NVAX 6
  • Target Price
  • SPRY $26.00
  • NVAX $17.83
  • AVG Volume (30 Days)
  • SPRY 1.2M
  • NVAX 3.7M
  • Earning Date
  • SPRY 03-20-2025
  • NVAX 02-27-2025
  • Dividend Yield
  • SPRY N/A
  • NVAX N/A
  • EPS Growth
  • SPRY N/A
  • NVAX N/A
  • EPS
  • SPRY N/A
  • NVAX N/A
  • Revenue
  • SPRY $2,568,000.00
  • NVAX $885,193,000.00
  • Revenue This Year
  • SPRY $68,783.34
  • NVAX N/A
  • Revenue Next Year
  • SPRY $503.87
  • NVAX N/A
  • P/E Ratio
  • SPRY N/A
  • NVAX N/A
  • Revenue Growth
  • SPRY 8460.00
  • NVAX N/A
  • 52 Week Low
  • SPRY $7.55
  • NVAX $3.81
  • 52 Week High
  • SPRY $18.51
  • NVAX $23.86
  • Technical
  • Relative Strength Index (RSI)
  • SPRY 37.72
  • NVAX 42.04
  • Support Level
  • SPRY $11.58
  • NVAX $7.70
  • Resistance Level
  • SPRY $12.43
  • NVAX $8.54
  • Average True Range (ATR)
  • SPRY 0.72
  • NVAX 0.39
  • MACD
  • SPRY -0.14
  • NVAX -0.04
  • Stochastic Oscillator
  • SPRY 0.53
  • NVAX 23.58

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Share on Social Networks: